ALK positive Non-Small Cell Lung Cancer (NSCLC) (DBCOND0167962)

Identifiers

Synonyms

ALK Positive Non-small Cell Lung Cancer / ALK-positive NSCLC / ALK-positive Non-small Cell Lung Cancer / ALK-positive Non-small Cell Lung Cancer (NSCLC)

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Alectinib	A kinase inhibitor used to treat anaplastic lymphoma kinase positive metastatic non small cell lung cancer.	ALK tyrosine kinase receptortarget Broad substrate specificity ATP-binding cassette transporter ABCG2transporter ATP-dependent translocase ABCB1transporter

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT06092086	Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC	Lorlatinib	treatment	2	recruiting
NCT05482087	A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC	No drug interventions	treatment	2	not_yet_recruiting
NCT03804541	The Absorption, Metabolism and Excretion of [14C]Ensartinib in Human	Ensartinib X-396	treatment	1	unknown_status
NCT02393625	Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer	Ceritinib Nivolumab	treatment	1	active_not_recruiting
NCT04647110	Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.	Alectinib Brigatinib Ceritinib Crizotinib Lorlatinib	Not Available	Not Available	completed
NCT04009317	Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)	Crizotinib	treatment	3	unknown_status
NCT04056572	Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib	No drug interventions	treatment	2	unknown_status
NCT02336451	A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges	Ceritinib	treatment	2	completed
NCT04211922	Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib	No drug interventions	treatment	2	terminated
NCT06361589	Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients	Lorlatinib	Not Available	Not Available	recruiting
NCT02513667	Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma	Ceritinib	treatment	2	terminated
NCT00585195	A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer	Crizotinib Itraconazole Rifampin	treatment	1	completed
NCT04979988	Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients	Lorlatinib	Not Available	Not Available	completed
NCT04900935	Patient-centered, Optimal Integration of Survivorship and Palliative Care	No drug interventions	supportive_care	Not Available	recruiting
NCT06410040	A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis	Lorlatinib	Not Available	Not Available	active_not_recruiting
NCT03131206	A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer	Alectinib	treatment	1 / 2	terminated